Febuxostat (vs. Allopurinol) In Treating the Hyperuricemia of Gout In Diabetic Patients.

被引：0
|
作者：
Becker, Michael A. [1 ]
MacDonald, Patricia A. [2 ]
Hunt, Barbara [2 ]
Jackson, Robert L. [2 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1022
引用
收藏
页码：S399 / S399
页数：1
相关论文
共 50 条
  • [21] COMPARISON OF COST OF ALLOPURINOL VS FEBUXOSTAT AS A FIRST LINE TREATMENT FOR GOUT
    Jutkowitz, E.
    Pizzi, L.
    Meltzer, M.
    VALUE IN HEALTH, 2010, 13 (03) : A123 - A123
  • [22] Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
    Kang, Eun Ha
    Park, Eun Hye
    Shin, Anna
    Song, Jung Soo
    Kim, Seoyoung C.
    EUROPEAN HEART JOURNAL, 2021, 42 (44) : 4578 - +
  • [23] CONVERSION FROM ALLOPURINOL TO FEBUXOSTAT IS BENEFIT FOR CKD PATIENTS WITH HYPERURICEMIA
    Kanai, Hidetoshi
    Harada, Kenji
    Tamura, Yasuhisa
    Kawai, Yasuhiro
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 138 - 138
  • [24] Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy
    M. Ruggeri
    M. Basile
    C. Drago
    F. R. Rolli
    A. Cicchetti
    PharmacoEconomics, 2018, 36 : 625 - 636
  • [25] CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
    White, William B.
    Chohan, Saima
    Dabholkar, Aruna
    Hunt, Barbara
    Jackson, Robert
    AMERICAN HEART JOURNAL, 2012, 164 (01) : 14 - 20
  • [26] Up-Titration of Allopurinol in the Febuxostat vs. Allopurinol Streamlined Trial (FAST)
    Jennings, Claudine
    Mackenzie, Isla S.
    Flynn, Rob
    Ford, Ian
    Nuki, George
    MacDonald, Thomas M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 424 - 425
  • [27] Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy
    Ruggeri, M.
    Basile, M.
    Drago, C.
    Rolli, F. R.
    Cicchetti, A.
    PHARMACOECONOMICS, 2018, 36 (05) : 625 - 636
  • [28] Prevalence of Treated Gout in Scotland, England and Denmark and Summary of Recruitment into the Febuxostat vs. Allopurinol Streamlined Trial (FAST)
    Jennings, Claudine
    Mackenzie, Isla S.
    Flynn, Rob
    Ford, Ian
    Nuki, George
    MacDonald, Thomas M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 400 - 401
  • [29] The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis
    Liu, Cheng-Wei
    Chang, Wei-Cheng
    Lee, Chiao-Chin
    Shau, Wen-Yi
    Hsu, Fu-Shun
    Wang, Man-Ling
    Chen, Tsung-Chih
    Lo, Chiao
    Hwang, Juey-Jen
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2019, 29 (10) : 1011 - 1022
  • [30] The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
    Steinberg, Alexandra S.
    Vince, Bradley D.
    Choi, Yun-Jung
    Martin, Robert L.
    McWherter, Charles A.
    Boudes, Pol F.
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (03) : 374 - 379
12345